Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.39 |
| ▸ | BRD4 | O60885 | 10/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 2/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.32 |
| ▸ | BRD2 | P25440 | 2/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.32 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20726366 | 0.77 | NEK1 (0.42) | EGFRBRD4AKT1 | |
| SCHEMBL20726459 | 0.76 | BRD4 (0.38) | EGFRBRD4AKT1KDRAURKA | |
| SCHEMBL20726393 | 0.76 | EGFR (0.39) | EGFRBRD4AKT1KDRAURKA | |
| SCHEMBL20726416 | 0.76 | ALOX5 (0.41) | EGFRBRD4KDRAURKAAURKB | |
| SCHEMBL20726384 | 0.75 | PDE3B (0.50) | EGFRBRD4KDR | |
| SCHEMBL20726441 | 0.75 | EGFR (0.40) | EGFRBRD4KDRBRD2PDPK1 | |
| SCHEMBL20726351 | 0.71 | BRD4 (0.41) | EGFRBRD4CHEK1 | |
| SCHEMBL20726370 | 0.71 | ACMSD (0.42) | EGFRBRD4KDRAURKAAURKB | |
| SCHEMBL20726350 | 0.70 | BRD4 (0.48) | EGFRBRD4AURKBBRD2CHEK1 | |
| SCHEMBL20726406 | 0.70 | EGFR (0.35) | EGFRBRD4AKT1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3083611-B1 | OXINDOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE IN THE TREATMENT OF AMPK-RELATED DISEASES | SANOFI SA (FR) | 2019-02-13 | — | — | EP | disclosed |